Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Liver transplantation for colorectal metastasis -selection criteria, outcomes, and management recurrence: a systematic review and meta-analysis.

Liver transplantation for colorectal metastasis -selection criteria, outcomes, and management recurrence: a systematic review and meta-analysis. International journal of surgery (London, England) Sayed Ahmed, A. F., Wehrle, C. J., Ring, T., Wu, J., Hong, H., Nadeem, M. A., Byrne, M. M., Iuppa, G., Linganna, M. W., Esfeh, J. M., Smedman, T. M., Kamath, S., Khalil, M., Fujiki, M., Alejandro, R. H., Sasaki, K., Schlegel, A., Kwon, D. C., Miller, C., Line, P. D., Hashimoto, K., Aucejo, F. 2025

Abstract

Despite advances in systemic therapies, the prognosis for non-resectable colorectal liver metastases (nCRLM) remains poor, with a 5-year survival rate of only 10%. Liver transplantation (LT) has emerged as a potential curative option for select patients. This study evaluated survival outcomes, recurrence rates, prognostic factors, and quality of life (QoL) following LT for nCRLM.A comprehensive search was performed through PubMed, Scopus, and the Cochrane Library for studies available up to 4 October 2024. Eligible studies reported survival, recurrence, or QoL following LT for nCRLM. Risk of bias was evaluated using ROBINS-I and RoB 2. A random-effects model pooled overall survival (OS), disease-free survival (DFS), and recurrence rates. Heterogeneity and publication bias were examined using Cochran's Q and Egger tests.Out of 549 patients, 20 studies with 377 unique patients were selected. OS at 1, 3, and 5 years were 91%, 67%, and 54%. DFS: 65%, 38%, and 16%. Recurrence occurred in 52%. Favorable pre-transplant factors were linked to better OS. QoL varied, with fatigue, pain, and dyspnea reported post-transplantation.LT offers strong survival benefits in nCRLM. However, high recurrence rates highlight the need for strict selection using Oslo score and Metabolic Tumor Volume (MTV).

View details for DOI 10.1097/JS9.0000000000004018

View details for PubMedID 41342603